Patent · US Active

siRNA targeting synuclein, alpha (SNCA-1)

US7579458B2 · kind B2 · utility

58Cited by
2References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 25, 2007
Grant dateAug 25, 2009
Priority date
Expiry dateJul 25, 2027

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/11
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to SNCA-1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.